Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 3Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3NIH 1INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Other hematologic neoplasm 5Lymphoid 2Sarcoma 1

Conditions

Leukemia, Myeloid, Acute 3Sarcoma, Myeloid 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Promyelocytic, Acute 1

Interventions

venetoclax 47Cyclophosphamide 43Specimen Handling 42Cytarabine 41fludarabine 32Biopsy 31Azacitidine 25Rituximab 20Methotrexate 17fludarabine phosphate 16blinatumomab 16Vincristine 15Daunorubicin 15Dexamethasone 14ibrutinib 13Whole-Body Irradiation 13Prednisone 13Magnetic Resonance Spectroscopy 13Injections 13obinutuzumab 11merphos 11Mercaptopurine 11Filgrastim 11Calcium Dobesilate 11asciminib 10X-Rays 10Stem Cell Transplantation 10Mycophenolic Acid 10Doxorubicin 10decitabine and cedazuridine drug combination 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Mitoxantrone × Other hematologic neoplasm × 30 days × Clear all
NCT05848687 2026-06-03

TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II

Stanford University

Phase 1/2 Recruiting
90 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01371981 2026-06-02

Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 3 Completed
1,645 enrolled 32 charts
Other hematologic neoplasmSarcoma

Leukemia, Myeloid, Acute, Sarcoma, Myeloid

NCT02583893 2026-05-29

Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia

Thomas Jefferson University

Phase 2 Completed
39 enrolled 12 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02688140 2026-05-29

TUD-APOLLO-064

Technische Universität Dresden

Phase 3 Completed
133 enrolled
Other hematologic neoplasm

Leukemia, Promyelocytic, Acute

NCT02632708 2026-05-22

Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation

Servier

Phase 1 Active not recruiting
153 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡